Anti-Human BNIP3L Antibody Pair

Product Description: BCL2 interacting protein 3 like (BNIP3L) is a mitochondrial protein that contains a BH3 domain and acts as a pro-apoptotic factor. It interacts with anti-apoptotic proteins, including BCL2, and plays a crucial role in mitochondrial quality control and clearance during erythroid development. BNIP3L, along with BNIP3, mediates mitochondrial clearance by opening a pore in the mitochondrial double membrane, allowing for the translocation of lysosomal proteins from the cytoplasm to the mitochondrial matrix. This process is essential for maintaining mitochondrial integrity and preventing cellular damage. BNIP3L is associated with diseases such as hereditary leiomyomatosis and renal cell cancer, and its dysregulation can lead to various pathological conditions. The protein's interaction with necroptosis-associated kinase RIPK3 also suggests a role in necroptosis, a form of programmed cell death. Protein Function: Induces apoptosis. Interacts with viral and cellular anti-apoptosis proteins. Can overcome the suppressors BCL-2 and BCL-XL, although high levels of BCL-XL expression will inhibit apoptosis. Inhibits apoptosis induced by BNIP3. Involved in mitochondrial quality control via its interaction with SPATA18/MIEAP: in response to mitochondrial damage, participates in mitochondrial protein catabolic process (also named MALM) leading to the degradation of damaged proteins inside mitochondria. The physical interaction of SPATA18/MIEAP, BNIP3 and BNIP3L/NIX at the mitochondrial outer membrane regulates the opening of a pore in the mitochondrial double membrane in order to mediate the translocation of lysosomal proteins from the cytoplasm to the mitochondrial matrix. May function as a tumor suppressor [The Uniprot Consortium]